Logo image of STTK

SHATTUCK LABS INC (STTK) Stock Fundamental Analysis

NASDAQ:STTK - Nasdaq - US82024L1035 - Common Stock - Currency: USD

0.8334  -0.01 (-1.61%)

Fundamental Rating

2

Overall STTK gets a fundamental rating of 2 out of 10. We evaluated STTK against 555 industry peers in the Biotechnology industry. STTK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. STTK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year STTK has reported negative net income.
In the past year STTK has reported a negative cash flow from operations.
In the past 5 years STTK always reported negative net income.
STTK had a negative operating cash flow in each of the past 5 years.
STTK Yearly Net Income VS EBIT VS OCF VS FCFSTTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -91.50%, STTK is doing worse than 73.87% of the companies in the same industry.
The Return On Equity of STTK (-104.47%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -91.5%
ROE -104.47%
ROIC N/A
ROA(3y)-62.4%
ROA(5y)-42.55%
ROE(3y)-70.96%
ROE(5y)-48.25%
ROIC(3y)N/A
ROIC(5y)N/A
STTK Yearly ROA, ROE, ROICSTTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for STTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STTK Yearly Profit, Operating, Gross MarginsSTTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

STTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STTK has been increased compared to 1 year ago.
The number of shares outstanding for STTK has been increased compared to 5 years ago.
STTK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STTK Yearly Shares OutstandingSTTK Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
STTK Yearly Total Debt VS Total AssetsSTTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.90, we must say that STTK is in the distress zone and has some risk of bankruptcy.
STTK has a worse Altman-Z score (-6.90) than 67.57% of its industry peers.
There is no outstanding debt for STTK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.9
ROIC/WACCN/A
WACC8.93%
STTK Yearly LT Debt VS Equity VS FCFSTTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 9.08 indicates that STTK has no problem at all paying its short term obligations.
STTK has a better Current ratio (9.08) than 74.41% of its industry peers.
A Quick Ratio of 9.08 indicates that STTK has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.08, STTK is in the better half of the industry, outperforming 74.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.08
Quick Ratio 9.08
STTK Yearly Current Assets VS Current LiabilitesSTTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

STTK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.98%, which is quite impressive.
Looking at the last year, STTK shows a very strong growth in Revenue. The Revenue has grown by 69.40%.
The Revenue for STTK have been decreasing by -10.37% on average. This is quite bad
EPS 1Y (TTM)27.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.03%
Revenue 1Y (TTM)69.4%
Revenue growth 3Y-42.45%
Revenue growth 5Y-10.37%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, STTK will show a small growth in Earnings Per Share. The EPS will grow by 4.51% on average per year.
Based on estimates for the next years, STTK will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y29.93%
EPS Next 2Y18.02%
EPS Next 3Y8.22%
EPS Next 5Y4.51%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
STTK Yearly Revenue VS EstimatesSTTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2031 100M 200M 300M 400M
STTK Yearly EPS VS EstimatesSTTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

STTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year STTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STTK Price Earnings VS Forward Price EarningsSTTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STTK Per share dataSTTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y8.22%

More info and screens

0

5. Dividend

5.1 Amount

STTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SHATTUCK LABS INC

NASDAQ:STTK (7/3/2025, 8:11:10 PM)

0.8334

-0.01 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners60.97%
Inst Owner Change-0.98%
Ins Owners1.8%
Ins Owner Change0%
Market Cap39.92M
Analysts78.18
Price Target2.51 (201.18%)
Short Float %3.83%
Short Ratio7.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.42%
Min EPS beat(2)-13.57%
Max EPS beat(2)8.72%
EPS beat(4)3
Avg EPS beat(4)4.48%
Min EPS beat(4)-13.57%
Max EPS beat(4)22.37%
EPS beat(8)6
Avg EPS beat(8)6.07%
EPS beat(12)9
Avg EPS beat(12)7.15%
EPS beat(16)11
Avg EPS beat(16)10.41%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.59%
EPS NY rev (1m)-6.9%
EPS NY rev (3m)-8.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.67
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0.1
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -91.5%
ROE -104.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.4%
ROA(5y)-42.55%
ROE(3y)-70.96%
ROE(5y)-48.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.08
Quick Ratio 9.08
Altman-Z -6.9
F-Score4
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)129.93%
Cap/Depr(5y)216.43%
Cap/Sales(3y)603.92%
Cap/Sales(5y)369.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.03%
EPS Next Y29.93%
EPS Next 2Y18.02%
EPS Next 3Y8.22%
EPS Next 5Y4.51%
Revenue 1Y (TTM)69.4%
Revenue growth 3Y-42.45%
Revenue growth 5Y-10.37%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y16.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.1%
EBIT Next 3Y-2.06%
EBIT Next 5Y-7.32%
FCF growth 1Y45.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.45%
OCF growth 3YN/A
OCF growth 5YN/A